In the present study the role of endogenous nitric oxide (NO) was investigated, in the regulation of renal cortical blood flow (RCBF) in vivo in anaesthetized rats under conditions in which prostacyclin involvement had been eliminated. 2 Infusions of the NO synthesis inhibitor NG-monomethyl-L-arginine (MeArg) at 1 or 3 mg kg' mi -1, i.v., produced significant decreases in RCBF of 29 + 7% and 35 5%, respectively. These effects were reversed by co-infusion of a 3 fold excess of L-arginine (L-Arg).
Introduction
The endothelium releases several vasoactive agents which interact to regulate the underlying vascular smooth muscle tone, thus contributing to the control of blood pressure. One such agent is the labile humoral factor, endothelium-derived relaxing factor (EDRF), first described by Furchgott & Zawadzki (1980) . In many vascular beds in vitro, including the rabbit isolated ear (Griffith et al., 1988) , rat lung (Cherry & Gillis, 1987) , rat mesentery (Byfield et al., 1986) and rat kidney (Bhardwaj & Moore 1988; Burton et al., 1988) , a role for EDRF in the control of arteriolar resistance has been proposed. However, relatively little is known about the role of EDRF in the control of renal vascular resistance in vivo.
EDRF, which was recently identified as nitric oxide (NO) (Palmer et al., 1987) is formed from the terminal guanidino nitrogen atom(s) of L-arginine (L-Arg) (Palmer et al., 1988a,b) . NG-monomethyl-L-arginine (MeArg) , an inhibitor of arginine metabolism to nitrogen oxides (Hibbs et al., 1987) prevents the release of NO from vascular endothelial cells (Palmer et al., 1988a) . In the anaesthetized rabbit , rat (Whittle et al., 1989) and guinea-pig (Aisaka et al., 1989a) , and in the conscious rat (Gardiner et al., 1990a) , MeArg causes a sustained rise in blood pressure suggesting that resting blood pressure is modulated by a continuous basal release of NO. Moreover, MeArg infusion into the forearm of human volunteers reduces blood flow by 40% and attenuates the dilator responses to acetylcholine but not to glyceryl trinitrate (Vallance et al., 1989) . In the rabbit aorta and rat mesentery in vitro, N.-nitro-L-arginine methyl ester (NO2Arg) is a more potent inhibitor of endothelium-dependent vasodilatation than MeArg (Moore et al., 1990) . Although there is still debate as to whether EDRF is NO or a closely related substance Author for correspondence. such as a nitrosothiol (Myers et al., 1990) , the inhibition of EDRF formation by L-arginine analogues, such as MeArg or NO2Arg, lends support to the identity of EDRF as NO. We shall refer to EDRF as NO in this paper.
NO causes vasodilatation by stimulating the formation of guanosine 3':5'-cyclic monophosphate (cyclic GMP) and a role of NO in the regulation of renal haemodynamics in vivo has recently been demonstrated, using excretion of urinary cyclic GMP as a biological marker of NO activity .
In the present study we have employed MeArg and NO2Arg to elucidate the role of basal and stimulated release of NO in the haemodynamics of the renal cortex, using laser Doppler flowmetry for the continuous measurement of renal cortical blood flow. All animals were treated with indomethacin to eliminate any possible involvement of prostacyclin or other prostaglandins.
Methods

Surgical procedure
Male Wistar rats (Periflux PF3, Perimed, Stockholm, Sweden) , the principle of which has been previously described (Walder et al., 1990) . The probe, which was gently placed on the ventral surface of the capsule of the left kidney, was fixed to a mobile arm pivoted about a fixed axis so that it moved as the kidney moved, thus reducing respiratory artefacts. Blood flow was continuously recorded on a microcomputer and expressed in arbitrary perfusion units. Drug-induced changes in blood flow were measured as percent change in perfusion units (PU) or as the area under the curve (AUC) (calculated from recorded data with the computer software package Perisoft, Perimed, Sweden) and expressed as units. The use of the laser Doppler technique for measurement of blood flow was first described by Riva et al. (1972) and has been validated as a method for study of renal blood flow (Stern et al., 1977; Smits et al., 1986) . In particular relative changes in RCBF measured by laser Doppler flowmetry are closely correlated to absolute changes in total renal blood flow (as measured by electromagnetic flowprobes) or absolute changes in RCBF measured with radioactive microspheres (Smits et al., 1986) . In addition, removal of the capsule of the kidney is not a prerequisite to obtain reliable measurements of RCBF by laser Doppler flowmetry (Stern et al., 1977; Smits et al., 1986) .
Experimental design
Effects of NO synthesis inhibition After surgery, all animals were allowed to stabilize for 10min before receiving indomethacin (5mgkg-1, i.v.). Twenty min later infusions were started of either NG-monomethyl-L-arginine acetate (MeArg; i.v., n =6; i.v., n = 5) or N.-nitro-L-arginine methyl ester hydrochloride (NO2Arg; 30,ugkg-min-m, i.v.; n=4; or 300pgkg-1min-1, i.v., n = 5) at 0.04 ml min'-and continued throughout the experiment. These doses significantly elevate blood pressure in the anaesthetized rat in vivo, presumably via inhibition of NO formation (Walder et al., 1990; Whittle et al., 1990; Hecker et al., 1990) . After 20 min, the infusion of the NO synthesis inhibitors was continued but with a co-infusion of an excess of L-Arg (3 fold excess of L-Arg at either 3 or 10mgkg-1minm , i.v. for MeArg and a 100 fold excess of L-Arg at 3 or 30mgkg-1min-', i.v. for NO2Arg). In some control experiments, L-Arg or D-Arg (3, 10 or 30mgkg-min 1, i.v.; n = 3-9) were infused for 10min.
Effects of NO synthesis inhibition on stimulated release of NO Twenty min after indomethacin treatment, a submaximal dose of acetylcholine (ACh; lO1ugkg-min-1, i.v.) was infused at a rate of 0.1 ml min-for 3 min. This dose of ACh was repeated at 30 min and 60 min after the first dose. Ten min prior to the second ACh infusion, animals received either MeArg (3mgkg-'min-m, i.v.; n= 5) or NO2Arg (300 pgkg-1 min-', i.v.; n = 5), with the infusion continued throughout the experiment at a rate of 0.04 ml min--. Twenty min before the last ACh infusion, L-Arg was co-infused with either MeArg or NO2Arg at a dose of lOmgkg-'min-' or 30mg kg-min -, respectively. In some experiments, the endothelium-independent renal vasodilator, dopamine i.v.; n = 3) , was infused at a rate of 0.1 ml min-1, instead of ACh. In these experiments, the effect of only one of the inhibitors, namely NO2Arg, was studied. In order to control for the general vasoconstriction and rise in blood pressure induced by MeArg or NO2Arg, one group of animals received a bolus dose of endothelin-1 (ET-1; 1 nmol kg-1, i.v.; n = 4) which preceded the second dose of ACh by 10min. In this group, the animals received neither L-Arg nor a third infusion of ACh. In one group of experiments, the second infusion of ACh or dopamine was preceded by a 10min infusion of L-Arg (30 mgkg-' min , i.v.; n = 4-6).
Materials
Indomethacin was prepared as a 5mgkg-' solution in 5% w/v sodium bicarbonate. Sodium-thiopentone (Trapanal) was obtained from Byk Gulden (Konstanz, F.R.G.). ACh, L-Arg, NO2Arg, dopamine and indomethacin were obtained from Sigma (Poole, Dorset), MeArg was from Calbiochem (La Jolla, C.A., U.S.A.) and endothelin was from the Peptide Research Institute (Osaka, Japan).
Statistical comparisons
All values in the figures and text are expressed as mean + s.e.mean of n observations. Statistical comparisons of differences within the same animal (i.e. before and after treatment) were made by Student's t test for paired determinations; comparisons of differences between groups of animals were made by Student's t test for unpaired determinations. A P value of < 0.05 was considered significant.
Results
Mean resting values for mean arterial blood pressure (MAP) were 117 + 3 mmHg (n = 27), for heart rate were 401 + 6 beats min 1 (n = 27) and for renal cortical blood flow (RCBF) were 212 + 15 PU (n = 27). These values were unaffected by pretreatment with indomethacin (122 + 3 mmHg, n = 27, P > 0.05; 391 + 7 beats minm , n = 27, P > 0.05; and 199 + 16PU, n = 27, P > 0.05).
Effects of NO synthesis inhibition Infusion of MeArg (lmgkg-1min-1, i.v., n = 6; or accompanied by concomitant decreases in RCBF of 29 + 7% (45 + 11 PU) and 35 + 5% (56 + 8 PU) which were not significantly different from each other. When calculated as change in conductance, MeArg (1 or 3 mgkg-1 min-1) decreased renal vascular conductance by 43 + 7% and 56 + 4%, respectively. These values were also not significantly different from each other, suggesting that the low dose of MeArg (1 mgkg1 min-1) was sufficient to achieve a maximal effect on RCBF. These reductions in RCBF were reversed by a 3 fold excess of L-Arg. An infusion of 10mgkg-'min'1 of L-Arg not only reversed the effects of MeArg, but resulted in a 49 + 10% increase in RCBF (Figure 2a ). However, L-Arg had some vasodilator role of its own. Infusions of L-Arg (3, 10 and 30 mg kg-' min -1; n = 3-5) for 10min significantly increased RCBF by 28 + 3 PU, 47 + 7 PU, 59 + 3 PU, respectively (P < 0.05). The same doses of D-Arg did not significantly increase RCBF (18 + 1 PU, 14 + 2 PU, 29 + 8 PU, respectively) when compared to saline (9 + 5 PU) (n = 3-9).
When compared to MeArg (1 mgkg-min-1, i.v.), NO2Arg
(300ug kg min-1, i.v.; n = 5) produced a similar increase in MAP of 34 + 7 mmHg indicating that NO2Arg is approximately 3 fold more potent than MeArg ( Figure lb ). An infusion of a 100 fold excess of L-Arg (30mgkg-1 min-1), however, failed to reverse the pressor effect of NO2Arg. This dose of NO2Arg had a much greater effect on RCBF than
MeArg (1 mgkg-' min-'), significantly reducing it by 53 + 4%
(95 + 16 PU) (Figure 2b conductance by 28 + 8%. The decreases in RCBF achieved with NO2Arg were significantly reversed by a 100 fold excess of L-Arg (Figure 2b ).
Effect of NO synthesis inhibition on stimulated release of NO Figure 4 illustrates the fall in blood pressure in response to 3 min infusions of ACh in the presence and absence of MeArg. Infusion of ACh (1 0ugkg-min-, i.v.; n = 14) for 3min resulted in a fall of MAP, which at maximum was 46 + 2 mmHg and was 35 + 3 mmHg after 3 min of infusion. This fall in MAP was not associated with any significant change in heart rate (P > 0.05; data not shown). Although MeArg (3mg kg-min-', i.v.) had no effect on the maximum fall in MAP induced by ACh, it did, however, reduce the duration of the response so that a significant inhibition was seen after 3 min of infusion (Figures 4 and 5a ). This inhibition was partially, but significantly, reversed by a 20 min infusion of
affect the maximum fall in MAP produced by ACh, but significantly reduced the duration of the response. This effect was significantly reversed by a co-infusion of a 100 fold excess of L-Arg (Figure 5b by MeArg. Likewise, the increase in MAP brought about by ET-1 was not significantly different from that induced by NO2Arg, even though the fall in RCBF was greater. Thus, the effects of ET-1 on either MAP or RCBF can be considered as a reasonable control for the changes brought about by both MeArg and NO2Arg. This injection of ET-1 (1 nmol kg'-) did not significantly affect the depressor response to ACh at 3 min ( Figure 5c ). The renal cortical hyperaemia induced by ACh was inhibited to some extent by a bolus dose of ET-1 (Inmolkg-; n=4) (16933 +2828 to 12019+ 2560 units). However, this was significantly different from the inhibition produced by MeArg and NO2Arg (P < 0.05; Figure 6c (c) The increase in RCBF produced by ACh was inhibited by endothelin-I (1 nmol kg-l). However, this inhibition was significantly weaker than the inhibition seen with MeArg or NO2Arg. (d) The increase in RCBF produced by dopamine (lOpgkg-' min-; for 3min) was not significantly affected by NO2Arg (300pgkg-1min-'). Data are expressed as means + s.e.mean. * P < 0.05 when compared to control; t P < 0.05 when compared to MeArg or NO2Arg. cant effect on MAP, either alone or in the presence of NO2Arg (300pgkg-min-l) ( Figure 5 ). However, an infusion of this dose of dopamine for 3 min resulted in an increase in renal cortical blood flow of 21 + 1% amounting to an AUC of 10468 + 880 units (n = 3), which was unaffected by NO2Arg (300pug kg -min -1) (10785 + 815 units) (Figure 6d) .
Infusions of high doses of L-Arg (30mg kg-min-, i.v.) did not affect the increase in RCBF induced by dopamine (7465 + 1115 to 6442 + 277 units, n = 4; P > 0.05). Although L-Arg potentiated the increase in RCBF induced by ACh in 3 out of 6 experiments, this effect failed to attain statistical significance (21951 + 1851 to 38509 + 7583 units, n = 6; P > 0.05). 
Discussion
After the discovery that aspirin-like drugs inhibit prostaglandin biosynthesis (Vane, 1971) , many workers studied their effects on renal blood flow, in order to define any prostaglandin contribution (see Patrono & Dunn, 1987) . There is now general agreement that prostaglandin formation does not contribute to normal renal blood flow but comes into play when the kidney is compromised, such as in circulatory shock or renal failure (Clive & Stoff, 1984; Carmichael & Shankel, 1985; Morrison, 1986; Patrono & Dunn, 1987; Oates et al., 1988) . Our results, in which indomethacin had no effect on renal cortical blood flow, fit into this general concept. From our results, the arginine-NO system clearly participates in the physiological maintenance of renal cortical blood flow. The present study demonstrates that the NO synthesis inhibitor, MeArg, reduced renal cortical blood flow (RCBF) in an L-Arg reversible manner. Moreover, NO2Arg produced a dose-dependent reduction in RCBF, which was partly reversed by L-Arg. In addition, both compounds inhibited endothelium-dependent (ACh), but not endotheliumindependent (dopamine) increases in RCBF in an L-Arg reversible manner. Most importantly, a low dose of NO2Arg, while having no pressor effect, considerably reduced RCBF.
Stimulated release of NO
ACh causes renal vasodilatation in isolated perfused kidneys (Burton et al., 1987; Bhardwaj & Moore, 1988; Burton et al., 1989) and in vivo (Baer et al., 1970; Baylis et al., 1976; Thomas et al., 1988; Walder et al., 1989) . In the isolated perfused kidney of the rat, the vasodilator response to ACh and the concomitant increase in urinary cyclic GMP are inhibited by haemoglobin or gossypol (Burton et al., 1990) . More importantly, in the anaesthetized rat in vivo, ACh induces a dosedependent increase in urinary cyclic GMP levels, the rates of increase of cyclic GMP being correlated with the fall in systemic blood pressure . The increase in urinary cyclic GMP levels, the hypotensive effect and renal haemodynamic effects of ACh are all inhibited by MeArg, suggesting that these effects of ACh are due to stimulation of NO formation, which then activates guanylate cyclase . This observation is supported by the work of Lahera et al. (1990) who also demonstrated that the AChinduced increase in renal blood flow and diuresis in the dog are inhibited by MeArg.
In the current study, the ACh-induced systemic hypotension and increase in RCBF were inhibited by MeArg or NO2Arg in an L-Arg reversible manner. Although ET-1, given to produce a similar pressor effect and fall in RCBF to that of MeArg or NO2Arg, produced a slight inhibition of the AChinduced increase in RCBF, this inhibition of the endotheliumdependent vasodilatation was significantly weaker than the one produced by MeArg or NO2Arg. This suggests that a vasoconstrictor agent, such as ET-1, can exert a weak functional antagonism of endothelium-dependent vasodilator responses. However, the main mechanism of action of the inhibition of endothelium-dependent vasodilator responses produced by MeArg or NO2Arg is most likely via specific inhibition of NO synthesis, for it was largely attenuated by L-Arg. Our finding here that the increase in RCBF induced by the endothelium-independent renal vasodilator dopamine (which acts via direct activation of cyclic AMP) was unaffected by NO2Arg supports this conclusion. In addition, infusion of the highest dose of L-Arg did not significantly affect the ACh-or dopamine-induced increases in RCBF. This suggests that the L-Arg reversal of the inhibitory effects of MeArg and NO2Arg on ACh-stimulated increases in RCBF are not due to direct effect of L-Arg.
Interestingly, the maximum systemic hypotensive effect produced by a 3 min infusion of ACh was unaffected by MeArg or NO2Arg, but the duration of the response was shortened. Similarly, MeArg does not affect the maximum hypotensive effect produced by bolus injections of ACh in the anaesthetized guinea-pig, but significantly shortens the response to the endothelium-dependent vasodilator (Aisaka et al., 1989b) . In contrast, Rees et al. (1989) clearly demonstrated that the maximum hypotensive effects of ACh were inhibited by MeArg in the anaesthetized rabbit. In addition, Whittle et al. (1989) have also shown that MeArg inhibits the maximum hypotensive effects of ACh, ET-1, substance P and bradykinin in the anaesthetized rat in vivo. Although in our study, MeArg or NO2Arg had only a weak inhibitor effect on the maximum systemic vasodilator responses brought about by ACh, it is clear that the ACh-induced increase in RCBF was largely attenuated by both inhibitors of NO formation. This finding indicates that the systemic hypotensive effect of ACh in vivo is only partly mediated by an ACh-stimulated release of NO. In support of this concept, NO2Arg (lOmgkg-1, i.v.) did not affect the fall in blood pressure produced by bolus injections of ACh in conscious rats (Gardiner et al., 1990c) .
When compared to MeArg, at a tenth of the dose, NO2Arg produced a similar inhibition of the duration of the hypotensive effect and inhibition of the increase in RCBF brought about by ACh. In addition, the effects of MeArg were reversed by a 3 fold excess of L-Arg, while the effects of NO2Arg were only partially reversed by a 100 fold excess of L-Arg. These results support the current hypothesis that NO2Arg is a more potent inhibitor of NO synthesis (Moore et al., 1990; Ishii et al., 1990; Hecker et al., 1990; Gardiner et al., 1990b) . The recent finding that bovine endothelial cells in culture metabolize MeArg, but not NO2Arg, to L-citrulline and subsequently to L-Arg may explain the differences in potency between MeArg and NO2Arg observed in vitro and in vivo (Hecker et al., 1990) .
Basal NO release
The substantial renal cortical vasoconstriction induced by the inhibition of arginine metabolism clearly indicates that the 'basal' release of NO is important for the regulation and maintenance of cortical blood flow in anaesthetized rats. Our findings here that MeArg or NO2Arg increase blood pressure, in an L-Arg reversible manner, are consistent with the current understanding that 'basal' NO release plays a major role in the modulation of systemic blood pressure in vivo Whittle et al., 1989; Aisaka et al., 1989; Vallance et al., 1989; Hecker et al., 1990; Gardiner et al., 1990a) .
Using laser Doppler flowmetry, we clearly demonstrate that the increases in MAP produced by MeArg or NO2Arg were accompanied by L-Arg reversible falls in RCBF (ranging from 21 to 53%) demonstrating a local role for NO in the control of RCBF. Similarly, MeArg (Gardiner et al., 1990a) and NO2Arg (Gardiner et al., 1990b) increase blood pressure and reduce total renal blood flow in the conscious rat chronically instrumented with pulsed Doppler flow probes. In contrast, Lahera et al. (1990) , using an electromagnetic flow probe to measure renal arterial blood flow showed that intrarenal infusion of low concentrations of MeArg (97pgkg-1min-1) had no effect on basal renal blood flow. Similarly, when renal plasma flow is measured by p-aminohippurate (PAH) clearance, an intravenous bolus injection of MeArg (15mgkg 1) failed to affect basal renal plasma flow . However, these studies (Lahera et al., 1990; did not separate cortical from medullary flow which may account for the differences in our data on the effects of MeArg on basal RCBF.
In the present study we demonstrated that infusions of LArg, but not D-Arg, produced an increase in RCBF. This finding is not entirely surprising, for it is well documented that the oral intake of protein or the infusion of amino acids, in particular L-Arg, induces an increase in renal plasma flow and glomerular filtration rate in various species including man, dogs and rats (Bosch et al., 1983; Palmore, 1983; Meyer & Brenner, 1983; Hostetter, 1986) . Interestingly, Bhardwaj & Moore (1989) showed that the vasodilator activity of L-Arg in the isolated perfused kidney of the rat can be abolished by removal of the endothelium. More recently, Tolins & Raij (1990) demonstrated that the increases in glomerular filtration rate and renal plasma flow, induced by amino acid infusion, were completely inhibited by intrarenal MeArg. Thus, on the one hand, NO may mediate some of the renal haemodynamic responses to L-Arg infusions. On the other hand, a direct vasodilator effect of L-Arg may contribute to some of its renal effects. At present it is not possible to differentiate between these two possibilities.
In addition, we have demonstrated that RCBF is much more sensitive than MAP to the effects of MeArg and NO2Arg and to reversal by L-Arg. More importantly, a low dose of NO2Arg, while having no systemic pressor effect, caused a 21% reduction in RCBF. This finding clearly indicates that the renal cortical vasculature has a relatively high basal release of NO, which substantially contributes to the regulation and maintenance of RCBF. Furthermore, our data here and our previous finding that MeArg and NO2Arg did not influence basal blood flow in the rat gastric vasculature (Walder et al., 1990) , indicate that the pressor responses to MeArg and NO2Arg in the anaesthetized rat in vivo are unlikely to be due to a uniform vasoconstriction in all vascular beds. Gardiner et al. (1990a,b) , using pulsed Doppler probes, also showed differential haemodynamic effects of MeArg and NO2Arg respectively, on renal, mesenteric and hindquarter vascular beds in the conscious rat. However, in those studies, the dose-dependent and long-lasting vasoconstrictions of both NO-inhibitors were more pronounced in the mesenteric than in the renal or hindquarter vascular beds.
It is still not clear whether the pressor responses to inhibitors of NO formation, such as MeArg, are entirely due to inhibition of 'basal' NO formation. Here, we demonstrate that MeArg and NO2Arg substantially reduce RCBF at very low doses. Such a reduction in RCBF may be associated with an activation of the renin/angiotensin system. Thus, another potential underlying mechanism of the pressor effects obtained with MeArg or NO2Arg in vivo may be related to an enhancement of renin/angiotensin II plasma levels secondary to a reduction in renal blood flow. However, recent work suggests that the renin/angiotensin II system is not responsible for the pressor effects of MeArg since the angiotensin II receptor antagonist, Sar-Gly-angiotensin II, did not prevent the rise in blood pressure induced by MeArg ).
In conclusion, our findings suggest that MeArg and NO2Arg inhibit basal and ACh-stimulated release of NO in the renal cortical vasculature. The discovery that NO2Arg can substantially reduce RCBF without having an effect on systemic blood pressure indicates that the renal cortical vasculature has a relatively high basal release of NO, which substantially contributes to the regulation and maintenance of RCBF.
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